HomeCompareCLVLF vs STAG

CLVLF vs STAG: Dividend Comparison 2026

CLVLF yields 0.39% · STAG yields 3.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLF wins by $332.1K in total portfolio value
10 years
CLVLF
CLVLF
● Live price
0.39%
Share price
$8.45
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.4K
Annual income
$233,845.04
Full CLVLF calculator →
STAG
STAG Industrial Inc.
● Live price
3.44%
Share price
$36.09
Annual div
$1.24
5Y div CAGR
0.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18.3K
Annual income
$462.22
Full STAG calculator →

Portfolio growth — CLVLF vs STAG

📍 CLVLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLFSTAG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLF + STAG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLF pays
STAG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLF
Annual income on $10K today (after 15% tax)
$32.77/yr
After 10yr DRIP, annual income (after tax)
$198,768.28/yr
STAG
Annual income on $10K today (after 15% tax)
$292.45/yr
After 10yr DRIP, annual income (after tax)
$392.89/yr
At 15% tax rate, CLVLF beats the other by $198,375.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLF + STAG for your $10,000?

CLVLF: 50%STAG: 50%
100% STAG50/50100% CLVLF
Portfolio after 10yr
$184.4K
Annual income
$117,153.63/yr
Blended yield
63.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on STAG right now

CLVLF
No analyst data
Altman Z
21.3
Piotroski
5/9
STAG
Analyst Ratings
9
Buy
9
Hold
3
Sell
Consensus: Buy
Price Target
$45.00
+24.7% upside vs current
Range: $39.00 — $59.00
Altman Z
1.2
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLF buys
0
STAG buys
0
No recent congressional trades found for CLVLF or STAG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLFSTAG
Forward yield0.39%3.44%
Annual dividend / share$0.03$1.24
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%0.3%
Portfolio after 10y$350.4K$18.3K
Annual income after 10y$233,845.04$462.22
Total dividends collected$320.5K$4.0K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: CLVLF vs STAG ($10,000, DRIP)

YearCLVLF PortfolioCLVLF Income/yrSTAG PortfolioSTAG Income/yrGap
1← crossover$10,777$77.10$10,665$345.09+$112.00CLVLF
2$11,687$155.31$11,364$357.70+$323.00CLVLF
3$12,820$314.80$12,098$370.43+$722.00CLVLF
4$14,363$645.46$12,869$383.28+$1.5KCLVLF
5$16,720$1,351.66$13,677$396.23+$3.0KCLVLF
6$20,831$2,941.08$14,524$409.27+$6.3KCLVLF
7$29,138$6,849.18$15,411$422.41+$13.7KCLVLF
8$49,086$17,907.69$16,339$435.61+$32.7KCLVLF
9$108,908$56,386.61$17,311$448.89+$91.6KCLVLF
10$350,377$233,845.04$18,327$462.22+$332.1KCLVLF

CLVLF vs STAG: Complete Analysis 2026

CLVLFStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLF Calculator →

STAGREIT

STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States. By targeting this type of property, STAG has developed an investment strategy that helps investors find a powerful balance of income plus growth.

Full STAG Calculator →
📬

Get this CLVLF vs STAG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLF vs SCHDCLVLF vs JEPICLVLF vs OCLVLF vs KOCLVLF vs MAINCLVLF vs PLDCLVLF vs EQRCLVLF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.